{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:34:24Z","timestamp":1790192064193,"version":"4.1.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11033-024-09418-4","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T07:01:53Z","timestamp":1712300513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity"],"prefix":"10.1007","volume":"51","author":[{"given":"Mohammad Mahdi Mokhtari","family":"Tabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Kazemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazal","family":"Bazregari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolmajid","family":"Ghasemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"9418_CR1","doi-asserted-by":"crossref","unstructured":"Islami F et al (2021) Annual report to the nation on the status of cancer, part 1: national cancer statistics JNCI: Journal of the National Cancer Institute, 113(12): p. 1648\u20131669","DOI":"10.1093\/jnci\/djab131"},{"issue":"1","key":"9418_CR2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL et al (2021) Cancer statistics, 2021. Ca Cancer J Clin 71(1):7\u201333","journal-title":"Ca Cancer J Clin"},{"issue":"1","key":"9418_CR3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","volume":"6","author":"Z Duan","year":"2021","unstructured":"Duan Z, Luo Y (2021) Targeting macrophages in cancer immunotherapy. Signal Transduct Target Therapy 6(1):127","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"9418_CR4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS (2020) Top 10 challenges in cancer immunotherapy. Immunity 52(1):17\u201335","journal-title":"Immunity"},{"issue":"8","key":"9418_CR5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z (2020) The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 17(8):807\u2013821","journal-title":"Cell Mol Immunol"},{"key":"9418_CR6","doi-asserted-by":"crossref","unstructured":"Macci\u00f2 A, Madeddu C (2023) Molecular Basis and Advances in Targeted Immunotherapy for Cancer. MDPI. p. 7802","DOI":"10.3390\/ijms24097802"},{"issue":"7","key":"9418_CR7","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.21873\/anticanres.15110","volume":"41","author":"KS Rallis","year":"2021","unstructured":"Rallis KS et al (2021) Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10. Anticancer Res 41(7):3247\u20133252","journal-title":"Anticancer Res"},{"issue":"5","key":"9418_CR8","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1007\/s12274-021-4031-6","volume":"15","author":"W Ban","year":"2022","unstructured":"Ban W et al (2022) Emerging systemic delivery strategies of oncolytic viruses: a key step toward cancer immunotherapy. Nano Res 15(5):4137\u20134153","journal-title":"Nano Res"},{"key":"9418_CR9","doi-asserted-by":"crossref","first-page":"153723","DOI":"10.1016\/j.prp.2021.153723","volume":"229","author":"S Taefehshokr","year":"2022","unstructured":"Taefehshokr S et al (2022) Cancer immunotherapy: challenges and limitations. Pathology-Research Pract 229:153723","journal-title":"Pathology-Research Pract"},{"key":"9418_CR10","doi-asserted-by":"crossref","unstructured":"Zarenezhad E et al (2023) Metallic nanoparticles: their potential role in breast Cancer immunotherapy via trained immunity provocation. Biomedicines, 11(5)","DOI":"10.3390\/biomedicines11051245"},{"issue":"11","key":"9418_CR11","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1007\/s11033-022-07633-5","volume":"49","author":"M Bahmanyar","year":"2022","unstructured":"Bahmanyar M et al (2022) Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review. Mol Biol Rep 49(11):10627\u201310633","journal-title":"Mol Biol Rep"},{"issue":"6","key":"9418_CR12","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE et al (2019) Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol 40(6):511\u2013523","journal-title":"Trends Immunol"},{"issue":"2","key":"9418_CR13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"issue":"8","key":"9418_CR14","doi-asserted-by":"crossref","first-page":"2202063","DOI":"10.1002\/adhm.202202063","volume":"12","author":"R Cheng","year":"2023","unstructured":"Cheng R, Santos HA (2023) Smart nanoparticle-based platforms for regulating Tumor Microenvironment and Cancer Immunotherapy. Adv Healthc Mater 12(8):2202063","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"9418_CR15","first-page":"514","volume":"42","author":"CL Ventola","year":"2017","unstructured":"Ventola CL (2017) Cancer immunotherapy, part 3: challenges and future trends. Pharm Ther 42(8):514","journal-title":"Pharm Ther"},{"issue":"4","key":"9418_CR16","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.annonc.2022.01.003","volume":"33","author":"A Patel","year":"2022","unstructured":"Patel A, Goldstein D, Tannock I (2022) Improving access to immunotherapy in low-and middle-income countries. Ann Oncol 33(4):360\u2013361","journal-title":"Ann Oncol"},{"key":"9418_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M et al (2020) cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol 13:1\u201311","journal-title":"J Hematol Oncol"},{"issue":"1","key":"9418_CR18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","volume":"80","author":"T Reisl\u00e4nder","year":"2020","unstructured":"Reisl\u00e4nder T, Groelly FJ, Tarsounas M (2020) DNA damage and cancer immunotherapy: a STING in the tale. Mol Cell 80(1):21\u201328","journal-title":"Mol Cell"},{"issue":"11","key":"9418_CR19","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.3390\/cancers12113123","volume":"12","author":"E-J Go","year":"2020","unstructured":"Go E-J et al (2020) Combination of irreversible electroporation and STING agonist for effective cancer immunotherapy. Cancers 12(11):3123","journal-title":"Cancers"},{"issue":"3","key":"9418_CR20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/med.21649","volume":"40","author":"JJ Wu","year":"2020","unstructured":"Wu JJ et al (2020) Agonists and inhibitors of the STING pathway: potential agents for immunotherapy. Med Res Rev 40(3):1117\u20131141","journal-title":"Med Res Rev"},{"issue":"6","key":"9418_CR21","doi-asserted-by":"crossref","first-page":"5977","DOI":"10.1021\/acs.chemrev.1c00750","volume":"122","author":"KM Garland","year":"2022","unstructured":"Garland KM, Sheehy TL, Wilson JT (2022) Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy. Chem Rev 122(6):5977\u20136039","journal-title":"Chem Rev"},{"issue":"23","key":"9418_CR22","doi-asserted-by":"crossref","first-page":"2201895","DOI":"10.1002\/advs.202201895","volume":"9","author":"T Su","year":"2022","unstructured":"Su T et al (2022) Responsive multivesicular polymeric nanovaccines that codeliver STING agonists and neoantigens for combination tumor immunotherapy. Adv Sci 9(23):2201895","journal-title":"Adv Sci"},{"issue":"41","key":"9418_CR23","doi-asserted-by":"crossref","first-page":"eabf6290","DOI":"10.1126\/sciadv.abf6290","volume":"7","author":"Y Yang","year":"2021","unstructured":"Yang Y et al (2021) ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. Sci Adv 7(41):eabf6290","journal-title":"Sci Adv"},{"key":"9418_CR24","doi-asserted-by":"crossref","unstructured":"Pan X et al (2023) Strategies involving STING pathway activation for cancer immunotherapy: mechanism and agonists. Biochem Pharmacol, : p. 115596","DOI":"10.1016\/j.bcp.2023.115596"},{"issue":"43","key":"9418_CR25","doi-asserted-by":"crossref","first-page":"e202210988","DOI":"10.1002\/anie.202210988","volume":"61","author":"YY Ling","year":"2022","unstructured":"Ling YY et al (2022) Simultaneous photoactivation of cGAS-STING pathway and pyroptosis by platinum (II) triphenylamine complexes for Cancer Immunotherapy. Angew Chem Int Ed 61(43):e202210988","journal-title":"Angew Chem Int Ed"},{"key":"9418_CR26","doi-asserted-by":"crossref","unstructured":"Zheng W et al (2023) How the Innate Immune DNA sensing cGAS-STING pathway is involved in apoptosis. Int J Mol Sci, 24(3)","DOI":"10.3390\/ijms24033029"},{"key":"9418_CR27","doi-asserted-by":"crossref","unstructured":"Ou L et al (2021) The cGAS-STING pathway: a promising Immunotherapy Target. Front Immunol, 12","DOI":"10.3389\/fimmu.2021.795048"},{"issue":"9","key":"9418_CR28","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41577-021-00524-z","volume":"21","author":"A Decout","year":"2021","unstructured":"Decout A et al (2021) The cGAS-STING pathway as a therapeutic target in inflammatory diseases. Nat Rev Immunol 21(9):548\u2013569","journal-title":"Nat Rev Immunol"},{"key":"9418_CR29","doi-asserted-by":"crossref","first-page":"814709","DOI":"10.3389\/fimmu.2021.814709","volume":"12","author":"N Liu","year":"2022","unstructured":"Liu N et al (2022) The cGAS-STING pathway in bacterial infection and bacterial immunity. Front Immunol 12:814709","journal-title":"Front Immunol"},{"key":"9418_CR30","doi-asserted-by":"crossref","unstructured":"Paulis A, Tramontano E (2023) Unlocking STING as a therapeutic antiviral strategy. Int J Mol Sci, 24(8)","DOI":"10.3390\/ijms24087448"},{"issue":"3","key":"9418_CR31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41594-023-00933-9","volume":"30","author":"DJ Patel","year":"2023","unstructured":"Patel DJ, Yu Y, Xie W (2023) cGAMP-activated cGAS\u2013STING signaling: its bacterial origins and evolutionary adaptation by metazoans. Nat Struct Mol Biol 30(3):245\u2013260","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"9418_CR32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/v13010021","volume":"13","author":"N Xia","year":"2020","unstructured":"Xia N et al (2020) African swine fever virus structural protein p17 inhibits cell proliferation through ER stress\u2014ROS mediated cell cycle arrest. Viruses 13(1):21","journal-title":"Viruses"},{"issue":"1","key":"9418_CR33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41392-021-00613-4","volume":"6","author":"R Zhang","year":"2021","unstructured":"Zhang R, Kang R, Tang D (2021) The STING1 network regulates autophagy and cell death. Signal Transduct Target Therapy 6(1):208","journal-title":"Signal Transduct Target Therapy"},{"issue":"5","key":"9418_CR34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/SHK.0000000000000771","volume":"47","author":"EL Heipertz","year":"2017","unstructured":"Heipertz EL, Harper J, Walker WE (2017) STING and TRIF contribute to mouse Sepsis, depending on severity of the Disease Model. Shock 47(5):621\u2013631","journal-title":"Shock"},{"issue":"8","key":"9418_CR35","doi-asserted-by":"crossref","first-page":"e29013","DOI":"10.1002\/jmv.29013","volume":"95","author":"R Zhang","year":"2023","unstructured":"Zhang R et al (2023) NLRC4 promotes the cGAS-STING signaling pathway by facilitating CBL-mediated K63-linked polyubiquitination of TBK1. J Med Virol 95(8):e29013","journal-title":"J Med Virol"},{"key":"9418_CR36","doi-asserted-by":"crossref","unstructured":"Tian M et al (2020) MYSM1 represses innate immunity and autoimmunity through suppressing the cGAS-STING pathway. Cell Rep, 33(3)","DOI":"10.1016\/j.celrep.2020.108297"},{"issue":"6","key":"9418_CR37","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s12094-022-03065-6","volume":"25","author":"X Song","year":"2023","unstructured":"Song X et al (2023) The stimulator of interferon genes (STING) agonists for treating acute myeloid leukemia (AML): current knowledge and future outlook. Clin Transl Oncol 25(6):1545\u20131553","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"9418_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13014-023-02335-z","volume":"18","author":"C Yang","year":"2023","unstructured":"Yang C et al (2023) Role of the cGAS-STING pathway in radiotherapy for non-small cell lung cancer. Radiat Oncol 18(1):145","journal-title":"Radiat Oncol"},{"key":"9418_CR39","doi-asserted-by":"crossref","first-page":"795401","DOI":"10.3389\/fimmu.2021.795401","volume":"12","author":"Y Gan","year":"2021","unstructured":"Gan Y et al (2021) The cGAS\/STING\u2002pathway: a Novel Target for Cancer Therapy. Front Immunol 12:795401","journal-title":"Front Immunol"},{"key":"9418_CR40","unstructured":"Liao X-W, Zhang S-Y, Zhang X (2009) IFN-\u03bb-newcomer to the interferon family"},{"issue":"7213","key":"9418_CR41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nature07317","volume":"455","author":"H Ishikawa","year":"2008","unstructured":"Ishikawa H, Barber GN (2008) STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455(7213):674\u2013678","journal-title":"Nature"},{"issue":"9","key":"9418_CR42","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1078-0432.CCR-10-1114","volume":"17","author":"S Hervas-Stubbs","year":"2011","unstructured":"Hervas-Stubbs S et al (2011) Direct effects of type I interferons on cells of the immune system. Clin Cancer Res 17(9):2619\u20132627","journal-title":"Clin Cancer Res"},{"key":"9418_CR43","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3389\/fphar.2018.01368","volume":"9","author":"S Bol\u00edvar","year":"2018","unstructured":"Bol\u00edvar S et al (2018) IFN-\u03b2 plays both pro-and anti-inflammatory roles in the rat cardiac fibroblast through differential STAT protein activation. Front Pharmacol 9:1368","journal-title":"Front Pharmacol"},{"key":"9418_CR44","doi-asserted-by":"crossref","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","volume":"179","author":"E Mantlo","year":"2020","unstructured":"Mantlo E et al (2020) Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 179:104811","journal-title":"Antiviral Res"},{"issue":"3","key":"9418_CR45","first-page":"373","volume":"5","author":"B Daniel","year":"2008","unstructured":"Daniel B, Stetson RM (2008) Type I interferons in host defense. Immunity 5(3):373\u2013381","journal-title":"Immunity"},{"key":"9418_CR46","doi-asserted-by":"crossref","first-page":"595739","DOI":"10.3389\/fimmu.2020.595739","volume":"11","author":"G Schreiber","year":"2020","unstructured":"Schreiber G (2020) The role of type I interferons in the pathogenesis and treatment of COVID-19. Front Immunol 11:595739","journal-title":"Front Immunol"},{"issue":"5","key":"9418_CR47","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3349\/ymj.2021.62.5.381","volume":"62","author":"H Choi","year":"2021","unstructured":"Choi H, Shin EC (2021) Roles of type I and III interferons in COVID-19. Yonsei Med J 62(5):381\u2013390","journal-title":"Yonsei Med J"},{"issue":"5","key":"9418_CR48","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","volume":"53","author":"Y-M Kim","year":"2021","unstructured":"Kim Y-M, Shin E-C (2021) Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med 53(5):750\u2013760","journal-title":"Exp Mol Med"},{"issue":"4","key":"9418_CR49","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.it.2021.02.003","volume":"42","author":"C King","year":"2021","unstructured":"King C, Sprent J (2021) Dual nature of type I interferons in SARS-CoV-2-induced inflammation. Trends Immunol 42(4):312\u2013322","journal-title":"Trends Immunol"},{"key":"9418_CR50","doi-asserted-by":"crossref","unstructured":"Latanova A, Starodubova E, Karpov V (2022) Flaviviridae nonstructural proteins: the role in Molecular mechanisms of triggering inflammation. Viruses, 14(8)","DOI":"10.3390\/v14081808"},{"issue":"6","key":"9418_CR51","doi-asserted-by":"crossref","first-page":"721","DOI":"10.4049\/jimmunol.2200746","volume":"210","author":"D Kim","year":"2023","unstructured":"Kim D et al (2023) IFN-Induced protein with tetratricopeptide repeats 2 limits autoimmune inflammation by regulating myeloid cell activation and metabolic activity. J Immunol 210(6):721\u2013731","journal-title":"J Immunol"},{"issue":"4","key":"9418_CR52","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1128\/JVI.01874-09","volume":"84","author":"F Diaz-San Segundo","year":"2010","unstructured":"Diaz-San Segundo F et al (2010) Interferon-induced protection against foot-and-mouth disease virus infection correlates with enhanced tissue-specific innate immune cell infiltration and interferon-stimulated gene expression. J Virol 84(4):2063\u20132077","journal-title":"J Virol"},{"key":"9418_CR53","doi-asserted-by":"crossref","unstructured":"Sher Y-P, Liu J-P, Liu S-J (2023) ADAM9 drives immunosuppressive environment for lung tumor progression. The Journal of Immunology","DOI":"10.4049\/jimmunol.210.Supp.172.08"},{"issue":"1","key":"9418_CR54","doi-asserted-by":"crossref","first-page":"e1515057","DOI":"10.1080\/2162402X.2018.1515057","volume":"8","author":"SH Kang","year":"2019","unstructured":"Kang SH et al (2019) Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma. Oncoimmunology 8(1):e1515057","journal-title":"Oncoimmunology"},{"key":"9418_CR55","doi-asserted-by":"crossref","unstructured":"Goetzke CC, Ebstein F, Kallinich T (2021) Role of proteasomes in inflammation. J Clin Med, 10(8)","DOI":"10.3390\/jcm10081783"},{"key":"9418_CR56","doi-asserted-by":"crossref","first-page":"1081288","DOI":"10.3389\/fnmol.2022.1081288","volume":"15","author":"J Yang","year":"2022","unstructured":"Yang J et al (2022) Mechanism and effects of STING-IFN-I pathway on nociception: a narrative review. Front Mol Neurosci 15:1081288","journal-title":"Front Mol Neurosci"},{"key":"9418_CR57","doi-asserted-by":"crossref","unstructured":"Rojas M et al (2021) The Landscape of IFN\/ISG Signaling in HIV-1-Infected macrophages and its possible role in the HIV-1 latency. Cells, 10(9)","DOI":"10.3390\/cells10092378"},{"key":"9418_CR58","doi-asserted-by":"crossref","first-page":"e20220044","DOI":"10.1590\/1678-9199-jvatitd-2022-0044","volume":"29","author":"KB Santiago","year":"2023","unstructured":"Santiago KB et al (2023) Propolis anti-inflammatory effects on MAGE-1 and retinoic acid-treated dendritic cells and on Th1 and T regulatory cells. J Venom Anim Toxins Incl Trop Dis 29:e20220044","journal-title":"J Venom Anim Toxins Incl Trop Dis"},{"issue":"44","key":"9418_CR59","doi-asserted-by":"crossref","first-page":"27509","DOI":"10.1073\/pnas.1921223117","volume":"117","author":"S Sun","year":"2020","unstructured":"Sun S et al (2020) Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U S A 117(44):27509\u201327515","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9418_CR60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3389\/fimmu.2019.00148","volume":"10","author":"BE Phillips","year":"2019","unstructured":"Phillips BE et al (2019) Tolerogenic dendritic cells and T-Regulatory cells at the clinical trials crossroad for the treatment of Autoimmune Disease; emphasis on type 1 diabetes therapy. Front Immunol 10:148","journal-title":"Front Immunol"},{"key":"9418_CR61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.15406\/moji.2018.06.00201","volume":"6","author":"A Chauhan","year":"2018","unstructured":"Chauhan A et al (2018) Interplay of vitamin D with T regulatory cells (FOXP3\u2009+\u2009Treg) and thymic stromal lymphopoietin (TSLP) in children with atopic diseases. MOJ Immunol 6:95\u201398","journal-title":"MOJ Immunol"},{"issue":"8","key":"9418_CR62","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1084\/jem.20172094","volume":"215","author":"K Stockenhuber","year":"2018","unstructured":"Stockenhuber K et al (2018) Foxp3(+) T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8(+) T cell response. J Exp Med 215(8):1987\u20131998","journal-title":"J Exp Med"},{"issue":"1","key":"9418_CR63","doi-asserted-by":"crossref","first-page":"17344","DOI":"10.1038\/s41598-023-43675-w","volume":"13","author":"F Saheb Sharif-Askari","year":"2023","unstructured":"Saheb Sharif-Askari F et al (2023) Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons. Sci Rep 13(1):17344","journal-title":"Sci Rep"},{"key":"9418_CR64","doi-asserted-by":"crossref","unstructured":"Keller P et al (2021) 861 reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy. BMJ Specialist Journals","DOI":"10.1136\/jitc-2021-SITC2021.861"},{"issue":"11","key":"9418_CR65","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1161\/CIRCRESAHA.116.309764","volume":"119","author":"MJ Butcher","year":"2016","unstructured":"Butcher MJ et al (2016) Atherosclerosis-driven Treg Plasticity results in formation of a dysfunctional subset of Plastic IFN\u03b3\u2009+\u2009Th1\/Tregs. Circ Res 119(11):1190\u20131203","journal-title":"Circ Res"},{"key":"9418_CR66","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3389\/fimmu.2019.01988","volume":"10","author":"Z Guo","year":"2019","unstructured":"Guo Z et al (2019) Inhibition of Cdk8\/Cdk19 activity promotes Treg Cell differentiation and suppresses autoimmune diseases. Front Immunol 10:1988","journal-title":"Front Immunol"},{"key":"9418_CR67","doi-asserted-by":"crossref","unstructured":"MA X et al (2023) AB0564 TIGIT ACTIVATOR ALLEVIATES SYSTEMIC LUPUS ERYTHEMATOSUS BY NEGATIVELY REGULATING TH1-LIKE TREG CELL DIFFERENTIATION. BMJ Publishing Group Ltd","DOI":"10.1136\/annrheumdis-2023-eular.619"},{"key":"9418_CR68","doi-asserted-by":"crossref","first-page":"S454","DOI":"10.1097\/01.tp.0000543247.08049.ba","volume":"102","author":"M Hu","year":"2018","unstructured":"Hu M et al (2018) Low dose IL-2 and Rapamycin leads to prolongation of human islet allograft survival by inhibition of IFN-gamma\u2009+\u2009T cells and expansion of FOXP3\u2009+\u2009CD25\u2009+\u2009Tregs in a humanized islet transplant mouse model. Transplantation 102:S454","journal-title":"Transplantation"},{"issue":"2","key":"9418_CR69","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/intimm\/dxaa058","volume":"33","author":"S Vitale","year":"2021","unstructured":"Vitale S et al (2021) Type I interferons induce peripheral T regulatory cell differentiation under tolerogenic conditions. Int Immunol 33(2):59\u201377","journal-title":"Int Immunol"},{"issue":"Suppl 3","key":"9418_CR70","first-page":"A622","volume":"72","author":"M Scarsi","year":"2013","unstructured":"Scarsi M et al (2013) SAT0122 reduction of Peripheral Blood G-Ifn and IL-17 producing T cells after therapy with Abatacept for Rheumatoid Arthritis. Ann Rheum Dis 72(Suppl 3):A622\u2013A622","journal-title":"Ann Rheum Dis"},{"issue":"40","key":"9418_CR71","doi-asserted-by":"crossref","first-page":"e202207175","DOI":"10.1002\/anie.202207175","volume":"61","author":"S Stazzoni","year":"2022","unstructured":"Stazzoni S et al (2022) Novel poxin stable cGAMP-Derivatives are remarkable STING agonists. Angew Chem Int Ed 61(40):e202207175","journal-title":"Angew Chem Int Ed"},{"issue":"4","key":"9418_CR72","doi-asserted-by":"crossref","first-page":"292","DOI":"10.18632\/oncotarget.27886","volume":"12","author":"AH Zaidi","year":"2021","unstructured":"Zaidi AH et al (2021) Intratumoral immunotherapy with STING agonist, ADU-S100, induces CD8\u2009+\u2009T-cell mediated anti-tumor immunity in an esophageal adenocarcinoma model. Oncotarget 12(4):292\u2013303","journal-title":"Oncotarget"},{"issue":"8","key":"9418_CR73","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1158\/2326-6066.CIR-17-0049","volume":"5","author":"CR Ager","year":"2017","unstructured":"Ager CR et al (2017) Intratumoral STING activation with T-cell checkpoint modulation generates systemic antitumor immunity. Cancer Immunol Res 5(8):676\u2013684","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"9418_CR74","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/2326-6066.CIR-19-0229","volume":"7","author":"R Falahat","year":"2019","unstructured":"Falahat R et al (2019) STING signaling in melanoma cells shapes antigenicity and can promote antitumor T-cell activity. Cancer Immunol Res 7(11):1837\u20131848","journal-title":"Cancer Immunol Res"},{"key":"9418_CR75","doi-asserted-by":"crossref","unstructured":"Nakamura T et al (2021) STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation Journal for immunotherapy of cancer, 9(7)","DOI":"10.1136\/jitc-2021-002852"},{"key":"9418_CR76","doi-asserted-by":"crossref","first-page":"996663","DOI":"10.3389\/fimmu.2022.996663","volume":"13","author":"Z Tian","year":"2022","unstructured":"Tian Z et al (2022) Cancer immunotherapy strategies that target the cGAS-STING pathway. Front Immunol 13:996663","journal-title":"Front Immunol"},{"issue":"2","key":"9418_CR77","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41416-021-01599-0","volume":"126","author":"EE Parkes","year":"2022","unstructured":"Parkes EE et al (2022) Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer. Br J Cancer 126(2):247\u2013258","journal-title":"Br J Cancer"},{"issue":"11","key":"9418_CR78","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3390\/cancers13112695","volume":"13","author":"A Amouzegar","year":"2021","unstructured":"Amouzegar A et al (2021) STING agonists as cancer therapeutics. Cancers 13(11):2695","journal-title":"Cancers"},{"issue":"10","key":"9418_CR79","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.4049\/jimmunol.1300097","volume":"190","author":"J Conlon","year":"2013","unstructured":"Conlon J et al (2013) Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol 190(10):5216\u20135225","journal-title":"J Immunol"},{"key":"9418_CR80","doi-asserted-by":"crossref","first-page":"969678","DOI":"10.3389\/fimmu.2022.969678","volume":"13","author":"PT Graham","year":"2022","unstructured":"Graham PT et al (2022) The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. Front Immunol 13:969678","journal-title":"Front Immunol"},{"issue":"5","key":"9418_CR81","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A et al (2023) Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 20(5):432\u2013447","journal-title":"Cell Mol Immunol"},{"key":"9418_CR82","doi-asserted-by":"crossref","unstructured":"Graham PT et al (2022) The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. Front Immunol, 13","DOI":"10.3389\/fimmu.2022.969678"},{"issue":"2","key":"9418_CR83","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4049\/jimmunol.1601999","volume":"199","author":"B Larkin","year":"2017","unstructured":"Larkin B et al (2017) Cutting Edge: activation of STING in T cells induces type I IFN responses and cell death. J Immunol 199(2):397\u2013402","journal-title":"J Immunol"},{"key":"9418_CR84","doi-asserted-by":"crossref","first-page":"795401","DOI":"10.3389\/fimmu.2021.795401","volume":"12","author":"Y Gan","year":"2022","unstructured":"Gan Y et al (2022) The cGAS\/STING pathway: a novel target for cancer therapy. Front Immunol 12:795401","journal-title":"Front Immunol"},{"key":"9418_CR85","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.12688\/f1000research.125163.1","volume":"11","author":"S Tripathi","year":"2022","unstructured":"Tripathi S et al (2022) cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. F1000Res 11:1010","journal-title":"F1000Res"},{"key":"9418_CR86","doi-asserted-by":"crossref","first-page":"1196829","DOI":"10.3389\/fimmu.2023.1196829","volume":"14","author":"E Papaevangelou","year":"2023","unstructured":"Papaevangelou E et al (2023) Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models. Front Immunol 14:1196829","journal-title":"Front Immunol"},{"key":"9418_CR87","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jare.2022.05.006","volume":"44","author":"X Kong","year":"2023","unstructured":"Kong X et al (2023) STING as an emerging therapeutic target for drug discovery: perspectives from the global patent landscape. J Adv Res 44:119\u2013133","journal-title":"J Adv Res"},{"issue":"14","key":"9418_CR88","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.3390\/molecules27144638","volume":"27","author":"K Luo","year":"2022","unstructured":"Luo K et al (2022) Activation of stimulation of interferon genes (STING) signal and cancer immunotherapy. Molecules 27(14):4638","journal-title":"Molecules"},{"issue":"11","key":"9418_CR89","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/cmdc.202100068","volume":"16","author":"DS Kim","year":"2021","unstructured":"Kim DS et al (2021) E7766, a macrocycle-bridged stimulator of Interferon genes (STING) agonist with potent Pan\u2010genotypic activity. ChemMedChem 16(11):1741\u20131744","journal-title":"ChemMedChem"},{"issue":"12Supplement","key":"9418_CR90","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1158\/1538-7445.AM2022-5320","volume":"82","author":"S Kazerounian","year":"2022","unstructured":"Kazerounian S et al (2022) BRG399, a small molecule modulator of UBE2K demonstrated dose-dependent anti-cancer efficacy in an in vivo model for gastric cancer. Cancer Res 82(12Supplement):5320\u20135320","journal-title":"Cancer Res"},{"issue":"13Supplement","key":"9418_CR91","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1158\/1538-7445.AM2019-3269","volume":"79","author":"K-C Huang","year":"2019","unstructured":"Huang K-C et al (2019) Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration. Cancer Res 79(13Supplement):3269\u20133269","journal-title":"Cancer Res"},{"issue":"1","key":"9418_CR92","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41392-022-01252-z","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z et al (2022) Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy. Signal Transduct Target Ther 7(1):394","journal-title":"Signal Transduct Target Ther"},{"key":"9418_CR93","doi-asserted-by":"crossref","unstructured":"Du H, Xu T, Cui M (2021) cGAS-STING signaling in cancer immunity and immunotherapy, vol 133. Biomedicine & Pharmacotherapy, p 110972","DOI":"10.1016\/j.biopha.2020.110972"},{"issue":"1","key":"9418_CR94","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41392-021-00613-4","volume":"6","author":"R Zhang","year":"2021","unstructured":"Zhang R, Kang R, Tang D (2021) The STING1 network regulates autophagy and cell death. Signal Transduct Target Ther 6(1):208","journal-title":"Signal Transduct Target Ther"},{"issue":"16Supplement","key":"9418_CR95","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1158\/1538-7445.AM2020-592","volume":"80","author":"K-C Huang","year":"2020","unstructured":"Huang K-C et al (2020) Demonstration of E7766, a novel STING agonist, as a potent immunotherapy in BCG-insensitive non-muscle invasive bladder cancer models via intravesical administration. Cancer Res 80(16Supplement):592\u2013592","journal-title":"Cancer Res"},{"issue":"6506","key":"9418_CR96","doi-asserted-by":"crossref","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","volume":"369","author":"B-S Pan","year":"2020","unstructured":"Pan B-S et al (2020) An orally available non-nucleotide STING agonist with antitumor activity. Science 369(6506):eaba6098","journal-title":"Science"},{"issue":"23","key":"9418_CR97","doi-asserted-by":"crossref","first-page":"e202300405","DOI":"10.1002\/cmdc.202300405","volume":"18","author":"C Xuan","year":"2023","unstructured":"Xuan C, Hu R (2023) Chemical Biology perspectives on STING agonists as Tumor Immunotherapy. ChemMedChem 18(23):e202300405","journal-title":"ChemMedChem"},{"issue":"11","key":"9418_CR98","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.3390\/v15112138","volume":"15","author":"H Lin","year":"2023","unstructured":"Lin H et al (2023) A non-nucleotide STING agonist MSA-2 synergized with manganese in enhancing STING activation to Elicit Potent Anti-RNA Virus Activity in the cells. Viruses 15(11):2138","journal-title":"Viruses"},{"issue":"1","key":"9418_CR99","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-022-01363-8","volume":"15","author":"M Yi","year":"2022","unstructured":"Yi M et al (2022) Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors. J Hematol Oncol 15(1):142","journal-title":"J Hematol Oncol"},{"issue":"1","key":"9418_CR100","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-020-00459-2","volume":"6","author":"J Liu","year":"2021","unstructured":"Liu J, Huang X, Ding J (2021) Identification of MSA-2: an oral antitumor non-nucleotide STING agonist. Signal Transduct Target Ther 6(1):18","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"9418_CR101","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.lungcan.2009.03.027","volume":"65","author":"MJ McKeage","year":"2009","unstructured":"McKeage MJ et al (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid\/DMXAA) 1800\u00a0mg\/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65(2):192\u2013197","journal-title":"Lung Cancer"},{"key":"9418_CR102","first-page":"937","volume":"9","author":"ST Pan","year":"2015","unstructured":"Pan ST et al (2015) Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug Des Devel Ther 9:937\u2013968","journal-title":"Drug Des Devel Ther"},{"issue":"5","key":"9418_CR103","first-page":"2055","volume":"13","author":"S Huang","year":"2023","unstructured":"Huang S et al (2023) Disulfiram combined with chemoimmunotherapy potentiates pancreatic cancer treatment efficacy through the activation of cGAS-STING signaling pathway via suppressing PARP1 expression. Am J Cancer Res 13(5):2055","journal-title":"Am J Cancer Res"},{"issue":"5","key":"9418_CR104","first-page":"2055","volume":"13","author":"S Huang","year":"2023","unstructured":"Huang S et al (2023) Disulfiram combined with chemoimmunotherapy potentiates pancreatic cancer treatment efficacy through the activation of cGAS-STING signaling pathway via suppressing PARP1 expression. Am J Cancer Res 13(5):2055\u20132065","journal-title":"Am J Cancer Res"},{"issue":"3","key":"9418_CR105","first-page":"727","volume":"10","author":"Y Han","year":"2020","unstructured":"Han Y, Liu D, Li L (2020) PD-1\/PD-L1 pathway: current researches in cancer. Am J cancer Res 10(3):727","journal-title":"Am J cancer Res"},{"key":"9418_CR106","doi-asserted-by":"crossref","unstructured":"Luo K et al (2022) Activation of Stimulation of Interferon genes (STING) Signal and Cancer Immunotherapy. Molecules, 27(14)","DOI":"10.3390\/molecules27144638"},{"issue":"1","key":"9418_CR107","doi-asserted-by":"crossref","first-page":"1777624","DOI":"10.1080\/2162402X.2020.1777624","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J et al (2020) Trial watch: STING agonists in cancer therapy. Oncoimmunology 9(1):1777624","journal-title":"Oncoimmunology"},{"issue":"10","key":"9418_CR108","doi-asserted-by":"crossref","first-page":"2200040","DOI":"10.1002\/adtp.202200040","volume":"5","author":"D Lee","year":"2022","unstructured":"Lee D et al (2022) Harnessing cGAS-STING pathway for Cancer Immunotherapy: from bench to Clinic. Adv Ther 5(10):2200040","journal-title":"Adv Ther"},{"issue":"7","key":"9418_CR109","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/acs.jmedchem.1c02197","volume":"65","author":"W Chang","year":"2022","unstructured":"Chang W et al (2022) Discovery of MK-1454: a potent cyclic dinucleotide stimulator of Interferon genes agonist for the treatment of Cancer. J Med Chem 65(7):5675\u20135689","journal-title":"J Med Chem"},{"key":"9418_CR110","doi-asserted-by":"crossref","first-page":"S683","DOI":"10.1016\/j.annonc.2020.08.1087","volume":"31","author":"K Harrington","year":"2020","unstructured":"Harrington K et al (2020) 972TiP phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma. Ann Oncol 31:S683","journal-title":"Ann Oncol"},{"key":"9418_CR111","doi-asserted-by":"crossref","unstructured":"Meric-Bernstam F et al (2019) Phase ib study of MIW815 (ADU-S100) in combination with spartalizumab (PDR001) in patients (pts) with advanced\/metastatic solid tumors or lymphomas. American Society of Clinical Oncology","DOI":"10.1200\/JCO.2019.37.15_suppl.2507"},{"issue":"10","key":"9418_CR112","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1111\/1759-7714.14414","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C et al (2022) A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer. Thorac Cancer 13(10):1463\u20131470","journal-title":"Thorac Cancer"},{"issue":"1","key":"9418_CR113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07763-8","volume":"21","author":"S Jiang","year":"2021","unstructured":"Jiang S et al (2021) Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis. BMC Cancer 21(1):1\u20137","journal-title":"BMC Cancer"},{"key":"9418_CR114","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/EDBK_201319","volume":"38","author":"S Zimmermann","year":"2018","unstructured":"Zimmermann S et al (2018) Immune checkpoint inhibitors in the management of lung cancer. Am Soc Clin Oncol Educational Book 38:682\u2013695","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"1","key":"9418_CR115","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.esmoop.2020.100003","volume":"6","author":"A Ortega-Franco","year":"2021","unstructured":"Ortega-Franco A et al (2021) First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions. ESMO open 6(1):100003","journal-title":"ESMO open"},{"issue":"7","key":"9418_CR116","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1111\/cas.15845","volume":"114","author":"K Yano","year":"2023","unstructured":"Yano K, Shiotani B (2023) Emerging strategies for cancer therapy by ATR inhibitors. Cancer Sci 114(7):2709\u20132721","journal-title":"Cancer Sci"},{"key":"9418_CR117","doi-asserted-by":"crossref","unstructured":"Venugopala KN (2022) Targeting the DNA damage response Machinery for Lung Cancer Treatment. Pharmaceuticals (Basel), 15(12)","DOI":"10.3390\/ph15121475"},{"issue":"7Supplement","key":"9418_CR118","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1158\/1538-7445.AM2023-2265","volume":"83","author":"T Sen","year":"2023","unstructured":"Sen T (2023) STING pathway activation by ATR inhibition potentiates the antitumor immune response to anti-PD-L1 antibody in small cell lung cancer. Cancer Res 83(7Supplement):2265\u20132265","journal-title":"Cancer Res"},{"issue":"10","key":"9418_CR119","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.3390\/jcm9103323","volume":"9","author":"L Motedayen Aval","year":"2020","unstructured":"Motedayen Aval L et al (2020) Challenges and opportunities in the clinical development of STING agonists for cancer immunotherapy. J Clin Med 9(10):3323","journal-title":"J Clin Med"},{"key":"9418_CR120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01803-8","volume":"40","author":"Q Hu","year":"2021","unstructured":"Hu Q et al (2021) Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis. J Experimental Clin Cancer Res 40:1\u201311","journal-title":"J Experimental Clin Cancer Res"},{"issue":"8Supplement","key":"9418_CR121","doi-asserted-by":"crossref","first-page":"LB323","DOI":"10.1158\/1538-7445.AM2023-LB323","volume":"83","author":"AS Weston","year":"2023","unstructured":"Weston AS et al (2023) Abstract LB323: inhibition of ENPP1 using small molecule, SR-8541A, enhances the effect of checkpoint inhibition in cancer models. Cancer Res 83(8Supplement):LB323\u2013LB323","journal-title":"Cancer Res"},{"issue":"10","key":"9418_CR122","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers15102858","volume":"15","author":"B Li","year":"2023","unstructured":"Li B et al (2023) Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials. Cancers 15(10):2858","journal-title":"Cancers"},{"key":"9418_CR123","doi-asserted-by":"crossref","first-page":"781032","DOI":"10.3389\/fimmu.2021.781032","volume":"12","author":"G Mohseni","year":"2021","unstructured":"Mohseni G et al (2021) The function of cGAS-STING pathway in treatment of pancreatic cancer. Front Immunol 12:781032","journal-title":"Front Immunol"},{"issue":"17","key":"9418_CR124","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-17-2807","volume":"24","author":"YS Tan","year":"2018","unstructured":"Tan YS et al (2018) Mitigating SOX2-potentiated immune escape of head and neck squamous cell carcinoma with a STING-inducing nanosatellite vaccine. Clin Cancer Res 24(17):4242\u20134255","journal-title":"Clin Cancer Res"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-024-09418-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-024-09418-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T15:23:38Z","timestamp":1738682618000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-024-09418-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":124,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["9418"],"URL":"https:\/\/doi.org\/10.1007\/s11033-024-09418-4","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None to declare by the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"487"}}